Project Grant R21CA309007
Award Date 7/1/26
Completion Date 6/30/28
Dollars Obligated $422K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas Southwestern Medical Center a $688,012 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 1, 2026, with a completion date of May 31, 2031. This award supports the development of novel RPS23 (ribosomal protein S23) inhibitors for the treatment of acute myeloid leukemia (AML). The research leverages an integrated platform combining high-throughput phenotypic screening with rapid...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $421,685 project grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded August 1, 2025, with a completion date of July 31, 2027. This award supports research investigating the LIFR-LCN2 pathway as a novel mechanism of immune suppression in hepatocellular carcinoma (HCC). The research aims to elucidate how loss of LIFR upregulates LCN2, leading to...
- Federal Project Grant Award Summary Award Details: The National Cancer Institute (NCI) awarded a $473,372 Project Grant to The University of Texas MD Anderson Cancer Center under the Cancer Biology Research program (CFDA 93.396) effective April 8, 2026, with an anticipated completion date of March 31, 2031. The research will be conducted in Houston, Texas. Research Products and Services: This project delivers fundamental cancer biology research investigating proline transfer RNA (tRNA)...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded MD Anderson Cancer Center a $688,073 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2026, through May 31, 2031. The award funds computational research to reconstruct the evolutionary history of cancer metastases, led by Principal Investigator Dr. Peter Van Loo. The project develops novel molecular archeology of cancer approaches—computational methods that leverage DNA sequencing...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $192,240 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective August 1, 2025, through July 31, 2030. This award funds research to decode mosaic chromosomal alterations (MCAs) in lymphoid malignancy risk and outcomes. The project delivers comprehensive scientific investigation into somatic megabase-scale alterations detectable...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded MD Anderson Cancer Center a $706,739 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 2, 2026, with a completion date of May 31, 2031. This award supports fundamental research to unravel the molecular mechanisms underlying immunotherapy-associated myocarditis (ICI-myocarditis), a severe cardiac inflammation that can occur as a side effect of immune checkpoint inhibitor (ICI) cancer...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $370,173 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded September 9, 2025, with a completion date of August 31, 2030. This project delivers research and development of advanced genetic interaction measurement and characterization methodologies for cancer cells, with a primary focus on synthetic lethality as a...
- Federal Project Grant Award Summary The National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) awarded a $164,000 Project Grant to The University of Texas MD Anderson Cancer Center, effective September 1, 2025, through August 31, 2027. This award supports research investigating the clonal determinants of platinum/PARP inhibitor (PARPi) cross-resistance in high-grade serous ovarian cancer (HGSOC). The research utilizes a novel somatic mosaic genetically-engineered mouse model...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $621,632 Project Grant to The University of Texas MD Anderson Cancer Center under the Cancer Treatment Research program (CFDA 93.395) to investigate disulfidptosis, a previously unexplored form of regulated cell death in cancer therapy. The award, initiated June 17, 2026, and scheduled for completion May 31, 2031, supports research to elucidate the molecular and metabolic mechanisms underlying disulfidptosis in...